Shilpa Medicare Limited (IN:SHILPAMED)
:SHILPAMED
Want to see IN:SHILPAMED full AI Analyst Report?
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹501.60
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹79.58B
Enterprise Value₹85.93B
Total Cash (Recent Filing)₹535.50M
Total Debt (Recent Filing)₹5.93B
Price to Earnings (P/E)35.2
Beta0.94
Next Earnings
May 21, 2026EPS Estimate
3.3Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)7.01
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.70
Price to Sales (P/S)4.98
P/FCF Ratio-57.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.7
Revenue Forecast (FY)₹17.05B
Bulls Say, Bears Say
Bulls Say
High Gross MarginA 68.12% gross profit margin indicates durable pricing power or a favorable product mix in APIs and formulations. This high gross margin provides a lasting buffer versus raw-material inflation, enabling sustained R&D, contract-manufacturing investments, and resilience in operating leverage over months.
Improved Balance Sheet LeverageMaterial deleveraging and a 71.65% equity ratio strengthen financial flexibility. Lower leverage reduces interest cost risk and expands capacity to fund regulatory compliance, capex for complex manufacturing, or strategic investments—improving the company’s ability to execute medium-term growth plans.
Consistent Revenue GrowthSustained top-line growth signals persistent demand for specialty/generic products and contract services. Durable revenue expansion supports scale economics, funds pipeline development and R&D, and diversifies risk across domestic and export channels, strengthening medium-term competitive positioning.
Bears Say
Weak Free Cash FlowSignificant capex-driven FCF decline and a negative FCF-to-net-income ratio weaken liquidity and cash conversion. If sustained, this can force external financing, constrain dividends or share buybacks, and limit the company’s ability to fund working capital or opportunistic investments over the next several months.
Eroding Operating MarginA sharp fall in EBIT margin despite high gross margins suggests rising operating costs or lower efficiency. Persistent margin erosion compresses operating cash conversion and return metrics, undermines reinvestment capacity, and poses a durable risk to profitability unless structural cost improvements are made.
Modest Net Margin And ReturnsA net margin of ~6% and ROE near single digits (3.30% reported) imply modest returns on equity and weak bottom-line conversion. Low returns limit the company’s ability to self-fund growth, reduce capital allocation flexibility, and may constrain shareholder return potential if efficiency doesn’t improve.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹501.60 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹79.58B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is May 21, 2026 which is in 17 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Feb 06, 2026. The company reported ₹2.28 earnings per share for the quarter, missing the consensus estimate of ₹2.8 by -₹0.52.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate is 3.3.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹2.28 in its last earnings report, missing expectations of ₹2.8. Following the earnings report the stock price went down -0.663%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―